Eli Lilly, Novo Nordisk Negotiating With Trump Over Weight Loss Drug Prices

The Trump administration is in negotiations with pharmaceutical companies Novo Nordisk and Eli Lilly to offer weight loss drugs at reduced prices through TrumpRx. According to sources familiar with the talks, the agreement could see a month's supply of these drugs priced at approximately $149, potentially benefiting some Medicare beneficiaries. Novo Nordisk produces the popular weight loss drug Wegovy, while Eli Lilly manufactures Zepbound.

The discussions, which are still ongoing, could lead to an official announcement soon. White House deputy press secretary Kush Desai stated that any discussions about unannounced deals should be viewed as speculative. However, press secretary Karoline Leavitt emphasized President Trump's commitment to reducing drug prices in the U.S.

Novo Nordisk confirmed its engagement in constructive discussions with the administration, focusing on improving patient access and affordability. Similarly, Eli Lilly is in talks to expand patient access and promote the affordability of its medicines. The negotiations follow President Trump's executive order in May, which aimed to enforce "most favored nation" pricing, ensuring U.S. patients are charged rates comparable to those in other countries.

An agreement could be announced as early as this week. The deal is part of ongoing efforts to address the high cost of medications in the United States.